Total Health
Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.
For more info visit our website at Total Health.
Philadelphia
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on CP-CML: Does Changing Ponatinib Dose Result in Improved OS?
FEATURING
Robert Redner
- 9 views
- October 19, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on mTNBC: Does Atezolizumab + Chemo Combo Improve PFS?
FEATURING
Elyse Lower
- 217 views
- October 13, 2020
- 2
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on MBC: Is Olaparib Beneficial for Disease With sBRCA1/2 or gPALB2 Mutations?
FEATURING
Elyse Lower
- 221 views
- October 13, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on HR+ MBC: Is Fulvestrant + CDKi Associated With Improved PFS and OS?
FEATURING
Elyse Lower
- 359 views
- October 13, 2020
- 3
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Cervical Cancer: Is SLN Biopsy Alone Oncologically Safe in Early Stage Disease?
FEATURING
Lainie Martin
- 114 views
- September 30, 2020
- 1
2020 ASCO Virtual Direct™ Highlights
ASCO 2020 Update on H&N Cancers: Are PFS and OS Prolonged With Tipifarnib?
FEATURING
Jessica Bauman
- 239 views
- September 18, 2020
- 1
2020 ASCO Virtual Direct™ Highlights
2020 Update on Esophagogastric Cancers: Did T-DXd Demonstrate Meaningful Clinical Improvements in ORR and OS vs. SoC Chemo in HER2+ Advanced Gastric/GEJ Cancer? Does the Addition of Ramucirumab to Perioperative FLOT Improve R0-resection Rates?
FEATURING
Daniel Lin
- 278 views
- August 13, 2020
- 2
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on Melanoma: How Effective Is the Combination of CTLA4 + PD-1 After Progression on PD-1 & Do We Need More Than 2 Doses? Is There a Long-Term Benefit of Adjuvant Dab + Tram in Resected Stage III BRAF V600E/K Melanoma?
FEATURING
Marlana Orloff
- 85 views
- August 20, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Follow Up on Advanced Melanoma: Should We Consider TIL as 2L / 3L Treatment Options?
FEATURING
Marlana Orloff
- 41 views
- August 13, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on mCRPC: Does LuPSMA Have More Compelling Clinical Activity Than Cabazitaxel?
FEATURING
Vivek Narayan
- 80 views
- August 24, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Aggressive B‐Cell Lymphomas: Does Venetoclax Boost Benefits of R‐EPOCH?
FEATURING
Jakub Svoboda
- 453 views
- August 6, 2020
- 4
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on HR+ BC: Does Neoadjuvant Endocrine Combination Therapy Have a Greater Effect on ESDR vs. Monotherapy in Early Stage BC? Should We Consider MammaPrint a Guidance Tool for Precision Adjuvant Therapy?
FEATURING
Kevin Kalinsky
- 523 views
- August 6, 2020
- 4
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on HER2+ MBC: Incorporating New HER2 Targeted Agents - Neratinib, Pertuzumab & T-DM-1
FEATURING
Kevin Kalinsky
- 220 views
- August 26, 2020
- 2